Breaking News Instant updates and real-time market news.

EIDX

Eidos Therapeutics

$36.56

-1.07 (-2.84%)

07:06
09/30/19
09/30
07:06
09/30/19
07:06

Eidos Therapeutics to present interim analysis of Phase 2 OLE study of AG10

Eidos Therapeutics announced that an interim analysis of its ongoing Phase 2 open-label extension study of AG10 in subjects with symptomatic ATTR cardiomyopathy will be presented in a late-breaking featured science oral presentation at this year's American Heart Association Scientific Sessions. Daniel Judge, M.D., professor in the division of cardiology at the Medical University of South Carolina, will discuss the data in a presentation entitled "Long-term Safety and Efficacy of AG10 in Patients with Transthyretin Amyloid Cardiomyopathy: Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study" at 5:30 PM ET on November 16, 2019 as part of the Early Phase Science oral session. In addition, Eidos will present several posters at AHA. The following summarizes Eidos' presentations at the conference: Long-term Safety and Efficacy of AG10 in Patients with Transthyretin Amyloid Cardiomyopathy: Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study. ATTRibute-CM: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Phase 3 Study of AG10 in Patients with Transthyretin Amyloid Cardiomyopathy. Differential Transthyretin Binding, Kinetic Stability and Additive Ex Vivo Stabilization by AG10 Compared to Tafamidis. Differential Ex Vivo Stabilization of Transthyretin by AG10 and Tafamidis in Samples from Patients with Moderate or Severely Destabilizing Mutations. AG10 is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to TTR amyloidosis, or ATTR. In a Phase 2 clinical trial in patients with symptomatic ATTR-CM, AG10 was generally well tolerated, demonstrated greater than 90 percent average TTR stabilization at Day 28, and increased serum TTR concentrations, a prognostic indicator of survival in a retrospective study of ATTR-CM patients, in a dose-dependent manner. AG10 was designed to mimic a naturally-occurring variant of the TTR gene that is considered a rescue mutation because co-inheritance has been shown to prevent or ameliorate ATTR in individuals also inheriting a pathogenic, or disease-causing, mutation in the TTR gene. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the stabilizing structure of this rescue mutation. The Phase 3 ATTRibute-CM study of AG10 in patients with ATTR-CM is underway. Part A of the study will assess the change from baseline in 6-minute walk distance at 12 months. Part B of the study will evaluate reduction in all-cause mortality and frequency of cardiovascular-related hospitalizations at 30 months. In addition, Eidos plans to initiate a Phase 3 study of AG10 in ATTR polyneuropathy by the end of 2019.

  • 02

    Oct

EIDX Eidos Therapeutics
$36.56

-1.07 (-2.84%)

05/07/19
ROTH
05/07/19
NO CHANGE
Target $51
ROTH
Buy
Eidos Therapeutics raised to $51 from $28 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Eidos Therapeutics (EIDX) to $51 from $28 driven by an increase in AG10's annual price from $150,000 to $225,000 and Probability of Success adjustment from 70% to 80% after Pfizer's (PFE) tafamadis received U.S. approval with a high sticker price of $225,000, two months ahead of schedule. The analyst believes this makes life easier for Eidos Therapeutics to maintain and even expedite enrollment into its Phase 3 ATTRibute-CM trial. Rahimi reiterates a Buy rating on Eidos Therapeutics shares.
07/22/19
PIPR
07/22/19
INITIATION
Target $55
PIPR
Overweight
Eidos Therapeutics initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren started Eidos Therapeutics with an Overweight rating and $55 price target. The analyst believes the ATTR cardiomyopathy class of drugs will generate several billion dollars in long-term sales. Eidos' AG10 should be best-in-class and the existing Phase II dataset supports this notion, Van Buren tells investors in a research note.
07/22/19
BMOC
07/22/19
NO CHANGE
Target $50
BMOC
Outperform
Eidos Therapeutics price target raised to $50 from $40 at BMO Capital
BMO Capital analyst George Farmer raised his price target on Eidos Therapeutics to $50 and kept his Outperform rating, saying the potential use of its AG10 was boosted by the "troubling" episodes of ocular-related adverse events around tafamidis treatment, as published in tafamidis NDA review and released by the FDA. The analyst further contends that AG10 is a "best-in-class TTR stabilizer" and offers a high likelihood of clinical success for treatment of TTR-mediated fibrotic diseases affecting the heart and the peripheral nervous system.
09/13/19
BTIG
09/13/19
NO CHANGE
Target $56
BTIG
Buy
Eidos Therapeutics price target raised to $56 from $38 at BTIG
BTIG analyst Thomas Shrader raised his price target on Eidos Therapeutics (EIDX) to $56 and kept his Buy rating after the decision by its board to reject an acquisition offer from parent company BridgeBio (BBIO) to buy all of its outstanding stock. The analyst notes that he always believed the combined entity would not be a more attractive investment, saying he is positive on the company's "declaration of independence". Shrader further cites the added revenue contribution expected from Eidos Therapeutics' deal with Alexion (ALXN) to develop and commercialize AG10 in Japan.

TODAY'S FREE FLY STORIES

12:05
11/13/19
11/13
12:05
11/13/19
12:05
General news
Powell didn't fully answer why analysts have low rates even as government spending increases »

Powell didn't fully…

DIS

Disney

$137.19

-1.37 (-0.99%)

12:04
11/13/19
11/13
12:04
11/13/19
12:04
Hot Stocks
Disney turns positive after announcing 10M streaming sign-ups »

The stock is up 15c to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$179.30

-0.49 (-0.27%)

, MA

MasterCard

$278.23

1.12 (0.40%)

12:04
11/13/19
11/13
12:04
11/13/19
12:04
Periodicals
FTC probing Visa, MasterCard over debit card transactions, Bloomberg reports »

Visa (V) and MasterCard…

V

Visa

$179.30

-0.49 (-0.27%)

MA

MasterCard

$278.23

1.12 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

DIS

Disney

$137.23

-1.33 (-0.96%)

12:03
11/13/19
11/13
12:03
11/13/19
12:03
Hot Stocks
Breaking Hot Stocks news story on Disney »

Disney says streaming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENR

Energizer

$47.45

5.44 (12.95%)

12:00
11/13/19
11/13
12:00
11/13/19
12:00
Hot Stocks
Energizer rises 13.2% »

Energizer is up 13.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 21

    Nov

SPB

Spectrum Brands

$60.10

8.91 (17.41%)

12:00
11/13/19
11/13
12:00
11/13/19
12:00
Hot Stocks
Spectrum Brands rises 17.0% »

Spectrum Brands is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

LN

Line Corp.

$49.79

9.12 (22.42%)

12:00
11/13/19
11/13
12:00
11/13/19
12:00
Hot Stocks
Line Corp. rises 21.9% »

Line Corp. is up 21.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRX

Catalyst Pharmaceuticals

$4.40

-0.51 (-10.39%)

11:57
11/13/19
11/13
11:57
11/13/19
11:57
Recommendations
Catalyst Pharmaceuticals analyst commentary  »

Catalyst Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CTAS

Cintas

$249.50

-9.4 (-3.63%)

11:56
11/13/19
11/13
11:56
11/13/19
11:56
Recommendations
Cintas analyst commentary  »

Baird says Cintas short…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$193.14

-1.33 (-0.68%)

11:55
11/13/19
11/13
11:55
11/13/19
11:55
Periodicals
China-owned TikTok is challenging Facebook for advertisers, Adweek says »

Adweek's platforms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIF

Tiffany

$122.85

-1.25 (-1.01%)

11:50
11/13/19
11/13
11:50
11/13/19
11:50
Options
Put sale in Tiffanys opens 100 strike block in Feb »

Put sale in Tiffanys…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:50
11/13/19
11/13
11:50
11/13/19
11:50
General news
Powell on the next downturn: generally the Fed has cut 500 bps in recessions »

Powell on the next…

TCDA

Tricida

$37.50

-2.21 (-5.57%)

11:49
11/13/19
11/13
11:49
11/13/19
11:49
Conference/Events
Tricida participates in a conference call with JPMorgan »

SMid Biotech Analyst Fye…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

ADPT

Adaptive Biotechnologies

$26.60

-1.75 (-6.17%)

11:47
11/13/19
11/13
11:47
11/13/19
11:47
Recommendations
Adaptive Biotechnologies analyst commentary  »

Adaptive Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

KNSA

Kiniksa

$6.62

-0.1 (-1.49%)

11:40
11/13/19
11/13
11:40
11/13/19
11:40
Conference/Events
Kiniksa participates in a conference call with JMP Securities »

JMP Securities hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

11:40
11/13/19
11/13
11:40
11/13/19
11:40
General news
Powell on max employment: the economy can operate at a much lower level of unemployment »

Powell on max employment:…

AAPL

Apple

$264.01

2.12 (0.81%)

, SJM

J.M. Smucker

$105.50

0.36 (0.34%)

11:36
11/13/19
11/13
11:36
11/13/19
11:36
On The Fly
Apple initiation, J.M. Smucker downgrade among today's top analyst calls »

Check out today's top…

AAPL

Apple

$264.01

2.12 (0.81%)

SJM

J.M. Smucker

$105.50

0.36 (0.34%)

TTWO

Take-Two

$119.53

0.53 (0.45%)

MOS

Mosaic

$20.05

-0.89 (-4.25%)

FCX

Freeport McMoRan

$10.93

-0.12 (-1.09%)

AA

Alcoa

$21.64

-0.545 (-2.46%)

ALB

Albemarle

$65.09

-0.19 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 19

    Nov

  • 21

    Nov

  • 22

    Nov

  • 12

    Dec

LYV

Live Nation

$64.81

0.055 (0.08%)

11:35
11/13/19
11/13
11:35
11/13/19
11:35
Hot Stocks
Live Nation, Rakuten partner to offer new members rewards and ticket offers »

Rakuten and Live Nation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIP

TripAdvisor

$30.77

-0.93 (-2.93%)

11:35
11/13/19
11/13
11:35
11/13/19
11:35
Options
TripAdvisor put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 26

    Nov

V

Visa

$179.73

-0.06 (-0.03%)

, MA

MasterCard

$279.01

1.9 (0.69%)

11:33
11/13/19
11/13
11:33
11/13/19
11:33
Periodicals
FTC probing Visa, MasterCard over debit card transactions, Bloomberg reports »

The Federal Trade…

V

Visa

$179.73

-0.06 (-0.03%)

MA

MasterCard

$279.01

1.9 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

EXEL

Exelixis

$16.18

0.84 (5.48%)

11:25
11/13/19
11/13
11:25
11/13/19
11:25
Options
Exelixis call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESRX

Express Scripts

$0.00

(0.00%)

11:25
11/13/19
11/13
11:25
11/13/19
11:25
Conference/Events
Detroit Economic Club to hold a luncheon meeting »

Tim Wentworth, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

11:20
11/13/19
11/13
11:20
11/13/19
11:20
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/13/19
11/13
11:17
11/13/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/13/19
11/13
11:16
11/13/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.